Alzheimer's drug fixes DNA damage and dampens brain inflammation in mice
King's College London researchers report that KCL-286, a drug originally developed for spinal cord injury, repaired DNA double-strand breaks and reduced brain inflammation in a mouse model of Alzheimer's, attacking multiple early disease pathways beyond amyloid and tau. Since it has already cleared Phase 1 safety testing for another condition, it could move more quickly into Alzheimer's clinical testing.
